

5,7,8-Trimethyl-benzopyran and 5,7,8-Trimethyl-1,4-benzoxazine Aminoamide Derivatives as Novel Antiarrhythmics against Ischemia–Reperfusion Injury

Eftychia N. Koini,[†] Panagiota Papazafiri,[‡] Athanasios Vassilopoulos,^{+,‡} Maria Koufaki,[†] Zoltán Horváth,^{||} István Koncz,[§] László Virág,[§] Gy J. Papp,^{§,||} András Varró,^{§,||} and Theodora Calogeropoulou^{*,†}

Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, 48 Vas. Constantinou Avenue, 116 35 Athens, Greece, Department of Animal and Human Physiology, School of Biology, University of Athens, Panepistimiopolis, 15784 Athens, Greece, Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged Dom ter 12 H-6720, Hungary, Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged Hungary

Received September 29, 2008

6-Hydroxy-5,7,8-trimethyl-benzopyran derivatives and 5,7,8-trimethyl-1,4-benzoxazine analogues substituted by the lidocaine pharmacophore aminoamide functionality at C4 or N4, respectively, were synthesized and evaluated against arrhythmias associated with ischemia–reperfusion injury. The antiarrhythmic effect of substituents at positions C2 and C6 was examined. Six out of the 11 new derivatives, exhibited arrhythmia scores 1.0–1.3 versus the control (4.5 ± 1.2), which was also reflected to the % premature beats (0.5–3.9), control (13.7 ± 3.6). Selected compounds were further studied by a conventional microelectrode method. 2-Diethylamino-1-(5,7,8-trimethyl-2-phenyl-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethanone (**50**) and the trolox-inspired 4-(2-diethylamino-acetyl)-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,4]oxazine-2-carboxylic acid ethyl ester (**62**) suppress reperfusion arrhythmias and reduce malondialdehyde (MDA) content, leading to a fast recovery of the heart after ischemia–reperfusion. They exhibit combined class IB and class III antiarrhythmic properties, which constitutes them as promising compounds for further studies because, due to their multichannel “amiodarone like” effect, less proarrhythmic complications can be expected.

Introduction

Acute myocardial ischemia causes highly arrhythmogenic changes in cardiac electrical properties^{1,2} that strongly promote ventricular tachycardias and ventricular fibrillation and lead to a high incidence of sudden death in minutes to hours.² Reperfusion through thrombolysis or percutaneous angioplasty (primary PTCA) is standard treatment in impending acute myocardial infarction.³ While early reperfusion of the heart is essential in preventing further tissue damage due to ischemia, reintroduction of blood flow can expedite the death of vulnerable, but still viable, myocardial tissue, by initiating a series of events involving both intracellular and extracellular mechanisms.^{4,5} The first few minutes of reperfusion constitute a critical phase, as lethal tissue injury in addition to that already developed during ischemia may be initiated. The manifestations of reperfusion injury include arrhythmia, reversible contractile dysfunction–myocardial stunning, endothelial dysfunction, and cell death. Reperfusion injury of the myocardium is a complex phenomenon consisting of several independent etiologies.⁶ The mechanisms proposed to contribute include oxygen free radical formation, calcium overload, neutrophil-mediated myocardial and endothelial injury, progressive decline in microvascular flow to the reperfused myocardium, and depletion of high energy phosphate

stores.⁷ Electrophysiological balance requires precise control of sarcolemmal ion channels and exchangers, many of which are regulated by phosphatidylinositol(4,5)bispophosphate, which is the immediate precursor of inositol(1,4,5)trisphosphate (IP₃), a regulator of intracellular Ca²⁺ signaling and, therefore, a potential contributor to arrhythmogenesis by altering Ca²⁺ homeostasis.^{7b} Recent studies have shown that both α_1 -adrenoceptor subtypes (α_{1A} -AR and α_{1B} -AR) can provide protection from IP₃ generation and arrhythmogenesis in early postischemic reperfusion through different mechanisms.^{7b,c}

A variety of compounds have been investigated in different experimental models of myocardial ischemia–reperfusion.⁸ These include oxygen free radical scavengers, antioxidants, calcium-channel blockers, inhibitors of neutrophils, nitric oxide, adenosine-related agents, inhibitors of the renin–angiotensin system, endothelin receptor antagonists, Na⁺/H⁺ exchange agents, mitochondrial K_{ATP} channel openers, and antiapoptotic agents. All of these categories of biologically active agents have been demonstrated to protect from reperfusion injury determined as limitation of infarct size, improved myocardial and endothelial function, and reduced incidence of arrhythmias.

It is now well recognized that arrhythmia is the main manifestation of ischemia and reperfusion myocardial dysfunction.⁹ In particular, reperfusion following a certain period of ischemia induces ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillation,¹⁰ which are different from coronary-evoked arrhythmias.¹¹ Lidocaine, a Na⁺ channel blocker, is often used as an antiarrhythmic drug in ischemia–reperfusion situations.¹² Besides having antiarrhythmic effects, lidocaine may protect myocardium not only against ischemic but also against reperfusion injury by affecting intracellular concentrations of sodium^{13,14} and calcium^{15,16} during ischemia and reperfusion, by protecting cellular membranes against long-chain acylcarnitines¹⁷ and reactive oxygen species,¹⁸ and perhaps

* To whom correspondence should be addressed. Phone: +3010 7273833. Fax: +30107273818. E-mail: tcalog@eie.gr.

[†] Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation.

[‡] Department of Animal and Human Physiology, School of Biology, University of Athens.

[§] Department of Pharmacology and Pharmacotherapy, University of Szeged.

^{||} Research Unit for Cardiovascular Pharmacology, Hungarian Academy of Sciences.

⁺ Current address: Genetics of Development, Disease Branch, National Institute of Diabetes, Digestive, Kidney Diseases, National Institutes of Health, Bethesda, Maryland, Maryland 20892.




Figure 1. Design of new 5,7,8-trimethylbenzopyran- and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives.


by blocking calcium channels.^{19,20} Lidocaine reduces myocardial ischemia—reperfusion injury in isolated rat heart^{21,22} and in vivo.^{23–27}

In our previous studies involving antiarrhythmic antioxidants,²⁸ the 6-hydroxy benzopyran ring of vitamin E and the pharmacophore diethylamino amide moiety of class I antiarrhythmics, procainamide and lidocaine, were combined in a single molecular entity. Among the new analogues, the lidocaine derivatives (**I**) were the most potent in suppressing reperfusion arrhythmias. As a continuation of our efforts in the field of novel cardioprotective agents against arrhythmias associated with ischemia—reperfusion injury,²⁹ we focused our studies on two classes of analogues. The first comprises 6-hydroxy-5,7,8-trimethylbenzopyran derivatives substituted by the lidocaine aminoamide functionality at C-4 (**II**), while the second encompasses 5,7,8-trimethyl-1,4-benzoxazine analogues in which the lidocaine aminoamide functionality constitutes part of the heterocyclic system (**III**). In addition, we studied the antiarrhythmic effect of alkyl or aryl substituents at position C2 as well as of substituents at position C6. (Figure 1). Selected compounds were further studied by a conventional microelectrode method in order to get insight into their cellular mode of action.


Chemistry

The synthesis of compounds **13–15**, **46–52**, **62**, and **63** is depicted in Schemes 1–5. More specifically, condensation of 3,6-dihydroxy-2,4,5-trimethyl acetophenone with acetone or 2-octanone in the presence of pyrrolidine and molecular sieves in ethanol gave chromanones **1** and **2**, respectively, while condensation of 3,6-dihydroxy-2,4,5-trimethyl acetophenone with benzaldehyde in the presence of piperidine, boric acid, and silica gel in DMF³⁰ afforded **3**. Compounds **1–3** upon treatment with hydroxylamine in pyridine were converted to oximes **4–6**, which were in turn reduced to the corresponding amines **7–9** using $\text{TiCl}_4/\text{NaBH}_4$ in DME.³¹ Analogues **7–9** were acylated using bromoacetyl chloride in the presence of NaHCO_3 in THF/ H_2O to afford bromoamides **10–12**, which reacted with diethylamine in toluene³² to produce the desired 4-aminobenzopyran derivatives **13–15**. The preparation of 1,4-benzoxazinone derivatives **20–23**, **25**, **26**, and **31** is depicted in Schemes 2 and 3. Thus, treatment of 2,3,5-trimethylphenol (**16**) with NaNO_3 in the presence of HCl and a catalytic amount of $\text{La}(\text{NO}_3)_3$ in a biphasic system (water—ether)³³ gave 2,3,5-trimethyl-6-nitrophenol (**17**), which was alkylated with the appropriate α -bromoester in the presence of Cs_2CO_3 and a catalytic amount of TBAI to give ethers **18**, **19**, and **24**. Hydrogenation of **18** and


19 gave the corresponding anilines, which spontaneously cyclized to benzoxazinones **20** and **21**, respectively. Reduction of the nitro group in compound **24** was effected using $\text{CuCl}/\text{NaBH}_4$ in ethanol³⁴ to give benzoxazinone **25** after spontaneous cyclization. Treatment of **20**, **21**, and **25** with a mixture of acetic acid/hydrogen peroxide/hydrogen chloride in petroleum ether afforded the 6-chloro-benzoxazinones **22**, **23**, and **26**. The synthesis of 2,3,5-trimethyl-6-nitro hydroquinone (**27**) was effected by hydroxylation of 2,3,5-trimethyl-6-nitro-phenol (**17**) using $\text{K}_2\text{S}_2\text{O}_8$ in 10% aqueous NaOH. Nitration of 2,3,5-trimethylhydroquinone afforded the corresponding quinone derivative instead of the 2,3,5-trimethyl-6-nitro hydroquinone. Efforts to nitrate 1,4-dimethoxy-2,3,5-trimethyl phenol resulted in deprotection and oxidation to the quinone, as previously observed.³⁵ Protection of the hydroxyl groups of **27** using dimethylsulfate in the presence of K_2CO_3 in acetone afforded the dimethoxy derivative **28**, which upon selective deprotection using $\text{BF}_3 \cdot \text{S}(\text{CH}_3)_2$ ³⁶ complex in CH_2Cl_2 yielded 4-methoxy-2,3,5-trimethyl-6-nitro-phenol (**29**). Alkylation with 2-bromo-2-phenyl methyl acetate, as above for compound **24**, afforded analogue **30**, which upon reduction using $\text{CuCl}/\text{NaBH}_4$ in ethanol³⁴ and spontaneous cyclization gave benzoxazinone **31**. The final aminoamide derivatives **46–52** were obtained as described in Scheme 4. Thus, reduction of benzoxazinones **20–23**, **25**, **26**, and **31** with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ and NaBH_4 in THF, at 0–5 °C, to the corresponding benzoxazines **32–38**, followed by acylation by bromoacetyl bromide in the presence of triethylamine in CH_2Cl_2 to give bromoamides **39–45** and subsequent treatment with diethylamine in toluene produced the final aminoamides **46–52**, respectively. The synthesis of compounds **62** and **63**, which can be envisaged as derivatives of trolox, the water soluble derivative of Vitamin E, was accomplished as depicted in Scheme 5. Alkylation of **17** using 2-bromo-2-methylmalonic acid diethyl ester to afford **53** was followed by catalytic hydrogenation to the corresponding aniline, which spontaneously cyclized to benzoxazinone **54**. Treatment of **54** with a mixture of acetic acid/hydrogen peroxide/hydrogen chloride in petroleum ether afforded the 6-chloro-benzoxazinone **55**. The desired benzoxazine derivatives **58** and **59** could not be obtained by treatment with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ and NaBH_4 or $\text{BH}_3 \cdot \text{THF}$ due to the concomitant reduction of the ester functionality at C2. We were able to circumvent this problem through formation of the corresponding thioamides **56** and **57** by treatment of **54** and **55**, respectively, with Lawesson reagent³⁷ followed by desulfurization using Ra/Ni to afford benzoxazines **58** and **59**, respectively. Acylation by bromoacetyl bromide in the presence of triethylamine in CH_2Cl_2 gave bromoamides **60** and **61**, and

Scheme 1^a

^a Reagents and conditions: (a) CH₃COR (R = CH₃ or C₆H₁₃), pyrrolidine, EtOH, molecular sieves, 50 °C; (b) PhCHO, H₃BO₃/piperidine, DMF, reflux; (c) NH₂OH·HCl, pyridine, 50 °C; (d) TiCl₄, NaBH₄, DME; (e) bromoacetyl chloride, NaHCO₃, THF/H₂O; (f) Et₂NH, toluene, 40 °C.

Scheme 2^a

^a Reagents and conditions: (a) NaNO₃, La(NO₃)₃, HCl, Et₂O; (b) R¹R²C(Br)COOCH₂CH₃, Cs₂CO₃, TBAI, DMF, 40 °C; (c) H₂, Pd/C, EtOH, 50 °C; (d) AcOH-H₂O₂-conc HCl, PE, reflux; (e) PhCH(Br)COOCH₃, Cs₂CO₃, TBAI, DMF; (f) NaBH₄, CuCl, EtOH, reflux.

Scheme 3^a

^a Reagents and conditions: (a) K₂S₂O₈, 10% aq NaOH; (b) (CH₃O)₂SO₂, K₂CO₃, TBAI, acetone, reflux; (c) BF₃·S(CH₃)₂, CH₂Cl₂, 0 °C; (d) PhCH(Br)COOCH₃, Cs₂CO₃, TBAI, DMF; (e) NaBH₄, CuCl, EtOH, reflux.


subsequent treatment with diethylamine in toluene produced the final aminoamides **62** and **63**, respectively.

The enantioselective synthesis of (*R*)-(-)-1-(6-chloro-5,7,8-trimethyl-2-phenyl-2,3-dihydro-benzo[1,4]oxazin-4-yl)-2-diethylamino-ethanone (**51b**) is described in Scheme 6. Chlorination of 2,3,5-trimethyl-6-nitrophenol (**17**) afforded 4-chloro-2,3,5-trimethyl-6-nitrophenol (**64**), which upon Mitsunobu reaction using (*S*)-(+)- α -hydroxy phenyl methyl acetate in the presence of triphenylphosphine and DEAD either at room temperature or at 40 °C afforded the desired *R*-enantiomer **65** but in low yield (~18%). The yield was dramatically increased when the reaction was performed in an ultrasonic bath (~75%).³⁸ The next step was the reduction of the nitro group in **65** followed by spontaneous cyclization to afford (*R*)-(-)-6-chloro-5,7,8-trimethyl-2-phenyl-2*H*-benzoxazine-3(4*H*)-one (**26b**). To this end, initially we employed CuCl in the presence of NaBH₄, which afforded benzoxazinone **26b** but unfortunately as a


racemic mixture, or Ra-Ni, which afforded the desired enantiomer of **26b** but in low yield (~40%). We were pleased to find that reduction of **65** using Fe in the presence of NH₄Cl³⁹ followed by spontaneous cyclization afforded benzoxazinone **26b**, in 70% yield, which upon reduction with BH₃·SMe₂ yielded benzoxazine **37b**. The desired amino amide **51b** was obtained after acylation by bromoacetyl bromide in the presence of triethylamine in CH₂Cl₂ and subsequent treatment with diethylamine in toluene.

Results and Discussion

The ability of the new analogues **13–15**, **46–52**, and **62** to suppress reperfusion arrhythmias and to inhibit lipid peroxidation was evaluated using the Krebs perfused Langendorff model⁴⁰ on isolated rat heart preparations (Tables 1 and 2). The results were obtained from 3–5 independent experiments. The compounds were present at the last 5 min of ischemia and during

Scheme 4^a

^a Reagents and conditions: (a) BF₃·Et₂O, NaBH₄, THF, 0–5 °C; (b) Bromoacetyl bromide, Et₃N, CH₂Cl₂; (c) Et₂NH, toluene, 40 °C.

Scheme 5^a

^a Reagents and conditions: (a) CH₃C(Br)(COOCH₂CH₃)₂, Cs₂CO₃, TBAI, DMF, 40 °C; (b) H₂, Pd/C, EtOH, 50 °C; (c) AcOH-H₂O₂-HCl, PE, reflux; (d) Lawesson reagent, toluene 110 °C; (e) Raney/nickel, EtOH-H₂O; (f) BrCH₂COBr, Et₃N, CH₂Cl₂; (g) Et₂NH, toluene, 40 °C.

Table 1. Antiarrhythmic and Antioxidant Activity of the New Analogues^a

compd	MDA (ng/g wet tissue)	arrhythmia score	premature ventricular beats PVB (%)	ventricular tachycardia (VT)	ventricular fibrillation (VF)
13	NE ^b		9 ± 3 (30 μM) 8 ± 5 (100 μM)		
14	NE		10 ± 3.5 (30 μM) 9 ± 4 (100 μM)		
15	128.6 ± 42.0	3.6 ± 0.86	4.3 ± 2.58 ^c (1 μM)	1.56 ± 0.24	
46	152.0 ± 29.0	1.3 ± 0.08 ^c	3.4 ± 2.25 ^c (1 μM)		
47	160.0 ± 1.0 ^c	5.1 ± 1.3	1.6 ± 0.64 ^c (1 μM)	0.84 ± 0.16	1.0 ± 0.13
48	163.0 ± 16.0	1.0 ± 0.09 ^c	3.9 ± 0.28 ^c (1 μM)		
49	143.0 ± 52	5.7 ± 1.00	2.1 ± 2.59 ^c (1 μM)		3.68 ± 0.21
50	120.0 ± 20.0 ^c	1.0 ± 0.01 ^c	0.5 ± 0.07 ^c (1 μM)		
51	118.3 ± 2.0 ^c	1.0 ± 0.05 ^c	1.0 ± 0.05 ^c (1 μM)		
52	136.0 ± 32.0	1.0 ± 0.03 ^c	2.8 ± 0.84 ^d (1 μM)		
62	88.6 ± 4.0 ^c	1.0 ± 0.02 ^c	3.0 ± 0.35 ^d (1 μM)		
control	230.0 ± 32.0	4.5 ± 1.24	13.0 ± 3.6 (1 μM)		
lidocaine	160.0 ± 40.0	1.0 ± 0.04	3.1 ± 1.0 (1 μM)		

^a n = 3–5. ^b NE = not examined. ^c *p < 0.05, versus control. ^d **p < 0.01, versus control. ^e ***p < 0.001, versus control.

reperfusion. Arrhythmia scores were calculated for the first 10 min of reperfusion and were quantified according to the Lambeth Convention guidelines⁴¹ by the following scoring system: hearts with premature ventricular beats (PVB^a) less than 5% were given a score of 1, with PVB more than 5% or bigeminy/salvos a score of 2, ventricular tachycardia (VT) a score of 3, transient ventricular fibrillation (VF) a score of 4, and sustained VF a score of 5. Ventricular fibrillations lasting more than 1 min were considered as sustained. The arrhythmia score in the absence of compound was 4.5 ± 1.24 and was mainly due to premature

beats (13.0 ± 3.6). Lidocaine had an arrhythmia score of 1.0 ± 0.04 and was also due to premature beats (3.1 ± 1.0).


Peroxidation of membrane phospholipid polyunsaturated fatty acids is considered a major mechanism of the damage occurring on reperfusion of the myocardium after a prolonged period of ischemia. Lipid peroxides are unstable and decompose to form a series of compounds including reactive carbonyl compounds. Malondialdehyde (MDA) is the final product of lipid peroxidation, and it has been found in the blood of patients after reperfusion of the myocardium.⁴² Thus, malondialdehyde quantitation by the thiobarbituric acid test (TBA test) has been used as indicator of lipid peroxidation.⁴³ Malondialdehyde (MDA) levels were measured at the end of reperfusion (ng/g wet tissue) (Tables 1,2), and the reduction of MDA levels was an indication of the antioxidant activity of the compounds under study.

^a Abbreviations: APA, action potential amplitude, APD₅₀, action potential duration measured at 50% repolarization; APD₉₀, action potential duration measured at 90% repolarization; MDA, malondialdehyde; PVB, premature ventricular beats; RMP, resting membrane potential, V_{max}, maximal rate of depolarization; VF, ventricular fibrillation, VT, ventricular tachycardia.

Table 2. Antiarrhythmic and Antioxidant Activity of the Racemic Mixture of Compound **51** and Its Enantiomers, **51a** and **51b**, Tested at 1 μ M Concentration^a

compd	MDA (ng/g wet tissue)	arrhythmia score	premature ventricular beats PVB (%)	ventricular tachycardia (VT)	ventricular fibrillation (VF)
51	118.3 \pm 2.0 ^b	1.0 \pm 0.05 ^b	1.0 \pm 0.05 ^b		
51a	106.0 \pm 6.0 ^b	4.3 \pm 1.34	1.5 \pm 1.32 ^c	2.64 \pm 0.32	0.3 \pm 0.08
51b	153.0 \pm 34.0	1.0 \pm 0.14 ^b	0.80 \pm 0.07 ^b		
control	230.0 \pm 32.0	4.5 \pm 1.24	13.0 \pm 3.6		
lidocaine	160.0 \pm 40.0	1.0 \pm 0.04	3.1 \pm 1.0		

^a $n = 3-5$. ^b $***p < 0.001$, versus control. ^c $**p < 0.01$, versus control.

**Figure 2.** Chiral HPLC separation of racemic **51**.

The activity of compounds **13–15**, **46–52**, and **62** against reperfusion arrhythmias and lipid peroxidation is presented in Table 1. Six out of the 11 new compounds induced only premature beats and therefore were given the arrhythmia score 1. When compared to the control value (13.0 \pm 3.6), these compounds reduced significantly the occurrence of PVBs, although to a different extent.

In more detail, within the first group, the 6-hydroxy-5,7,8-trimethyl-benzopyran-4-aminoamide compounds **13** and **14** were evaluated at 30 and 100 μ M and were found to possess low activity slightly suppressing premature beats. The levels of MDA were not measured because the compounds were not very potent. Conversely, introduction of a phenyl group at C2 resulted in increased activity and compound **15** at concentration of 2 μ M was found to reduce premature beats to 4.3 \pm 2.6 with respect to the control (13.0 \pm 3.6) and MDA levels by 45%. However, tachycardia was observed as a side effect. (Table 1). On the contrary, the 5,7,8-trimethyl-1,4-benzoxazine derivatives **46–52**, tested at 2 μ M (Table 1), were found to possess significant antioxidant and antiarrhythmic activity. The C2 and C6 unsubstituted derivative **46** reduced premature beats to 3.4 \pm 2.25 with an arrhythmia score of 1.3 \pm 0.1 versus the control (4.5 \pm 1.24) and MDA levels by 34%. Introduction of chlorine at C6, compound **48**, reduced MDA levels by 29% and premature beats to 3.9 \pm 0.28 with an arrhythmia score of 1.0 \pm 0.09.

The 2,2-dimethyl derivative **47** significantly suppressed premature beats (1.6 \pm 0.64) but caused tachycardia and ventricular fibrillation, resulting in an arrhythmia score of 5.1 \pm 1.3. The presence of a chlorine atom at C6 in **47** (compound **49**) caused also reduction of PVBs (2.1 \pm 2.59) and suppressed tachycardia but increased fibrillation (arrhythmia score 5.7 \pm 1.00). The antioxidant capacity of **47** and **49** was similar.

The 2-phenyl substituted analogues **50–52** exhibited the highest antioxidant and antiarrhythmic activity of all the compounds of the present study. Thus, derivative **50** decreased MDA levels by approximately 48% and PVBs to 0.5 \pm 0.07 (control PVB (%) = 13 \pm 3.6 and lidocaine PVB (%) = 3.1 \pm 1.0).


The C6 chloro-substituted analogue of **50** (compound **51**) reduced PVBs to a lesser extent than **50** (PVB = 1.0 \pm 0.05) but possessed slightly higher antioxidant activity (118.3 \pm 2.0 ng/g wet tissue). In addition, both compounds resulted in very good recovery of the heart. Analogue **52** is substituted by a methoxy group at C6 and caused a substantial decrease of PVBs and MDA in comparison to both the control and lidocaine (PVB = 2.8 \pm 0.84 and MDA = 136 \pm 32.0 ng/g wet tissue). However, when compared to **50** and **51**, the presence of the methoxy group was less advantageous than chlorine or hydrogen.

Because compound **51** was not only very potent in suppressing reperfusion arrhythmias but also was the most potent antioxidant (MDA 118.3 \pm 2.0 ng/g wet tissue), it was of interest to investigate whether the two enantiomers of **51** possessed different activity than the racemate. Thus we employed chiral HPLC (DAICEL-CHIRACEL OD, mobile phase hexane/2-propanol 90/10, flow rate 2.4 mL/min) for the separation of the racemic mixture (Figure 2). The first eluting enantiomer ($t_1 = 18.8$ min) **51a** ($[\alpha]_D^{20} = +41.3^\circ$) reduced the MDA levels more than 50% (106.0 \pm 6.0) and the PVBs to 1.5 \pm 1.32 but it caused tachycardia and fibrillation (Table 2). The second eluting enantiomer ($t_2 = 22.2$ min) **51b** ($[\alpha]_D^{20} = -42.8^\circ$) almost totally suppressed reperfusion arrhythmias PVB (%) = 0.80 \pm 0.07, reduced MDA (153.0 \pm 34.0), not as efficiently as **51a**, and resulted in very good recovery of the heart. To determine the absolute stereochemistry of the active enantiomer **51b**, we performed chiral synthesis, as depicted in Scheme 6, and it was found that compound **51b** was the *R*-enantiomer. It must be noted that even though the two enantiomers differed in activity, the racemic mixture was equally active as **51b**. This has been previously reported for the racemate of the β -adrenergic blocker and class III antiarrhythmic, sotalol and its dextro-rotatory isomer (*D*-sotalol), which were both equally effective in increasing cardiac action potential durations.⁴⁴

The antiarrhythmic and the antioxidant capacity of the trolox resembling derivative **62** were also measured using the same conditions (Table 1). This compound was found to possess the highest antioxidant capacity as reduced the level of MDA to approximately 40% of the control ($p < 0.001$), while its antiarrhythmic activity was similar to that of compounds **50–52**.

To get an insight on the mechanism of action of the potent 5,7,8-trimethyl-1,4-benzoxazine derivatives, we employed the conventional microelectrode technique to study their effects on the action potential parameters. More specifically, we selected the nonsubstituted at C2 and C6 compounds **46** and **47**, which bear two methyl groups at C2, **49**, which is the 6-chloro derivative of **47**, **50**, which has a phenyl substituent at C2, and the two trolox-resembling derivatives **62** and **63**.

The cellular electrophysiological effects of analogues **46**, **47**, **49**, **50**, **62**, and **63** were investigated using rabbit right ventricular papillary muscle at 5 μ M. As control, we employed the class I/B drug mexiletine, which is an orally active lidocaine analogue, and the class III antiarrhythmic sotalol, at 20 μ M concentration (Figure 3). The relation of the *in vitro* cellular action potential and *in vivo* ECG measurements is illustrated in Figure 4. The

Scheme 6^a

^a Reagents and conditions: (a) (S)-(+)-α-Hydroxy-phenyl-acetic acid methyl ester, Ph₃P, DEAD, THF, ultrasound; (b) Fe, NH₄Cl, EtOH/H₂O, 85 °C; (c) BH₃·SMe₂, THF; (d) BrCH₂COBr, Et₃N, CH₂Cl₂; (e) Et₂NH, toluene, 40 °C.




Figure 3. Structures of known antiarrhythmic drugs.

cellular electrophysiological results are illustrated and summarized in Table 3 and Figures 5 and 6. The compounds can be divided in three groups according to their effects. Thus, compounds **47** and **63** did not or only slightly changed the repolarization measured as APD₅₀ or APD₉₀ but exerted marked and use-dependent depression of the maximal rate of depolarization (V_{\max}) and increase of impulse conduction time (CT), particularly at fast stimulation frequencies. In this respect, it has to be noted that **47** decreased V_{\max} only at stimulation cycle lengths shorter than 1500–2000 ms, while, **63** decreased V_{\max} at all stimulation cycle lengths studied. These effects resemble those of mexiletine (Figure 6)⁴⁵ and flecainide,⁴⁶ are consistent with class I/B and class I/C properties⁴⁷ and strongly suggest considerable fast sodium channel inhibition. Compounds **46** and **49** induced a marked reverse rate dependent prolongation of repolarization measured as APD₉₀ without or only slightly changing V_{\max} or CT. This effect by **46** is similar to the class III reference compound sotalol (Figure 6) and is consistent with class III antiarrhythmic properties,⁴⁸ suggesting inhibition of one of the repolarizing cardiac potassium channels most likely the rapid delayed rectifier outward potassium current (I_{Kr}) flowing through the HERG channels. Compounds **50** and **62** showed considerable effect both on repolarization (APD₉₀) and depolarization/impulse conduction in a frequency dependent manner. Both analogues decreased V_{\max} and increased CT more at fast stimulation frequencies corresponding to cycle lengths of less than 2000 ms than at normal or slow ones, but they delayed repolarization reflected as increase of APD₉₀ somewhat more at slow than at fast stimulation frequencies. This combination of class IB and class III antiarrhythmic properties resembles to that of amiodarone⁴⁹ and suggests combined or multichannel drug action.

The 2,2-dialkyl-substituted-4-aminobenzopyrane derivatives **13** and **14** possessed similar antiarrhythmic activity as their 5-aminobenzopyrane congeners, previously reported by our group.²⁸ This suggests that the position of the aminoamide functionality in the 2,2-dialkyl-chroman derivatives is not very critical for activity against reperfusion arrhythmias. The presence of alkyl substituents at C2 resulted either in moderately active compounds, in the case of the 4-amino-benzopyran derivatives

13 and **14**, or in analogues that caused ventricular tachycardia and/or ventricular fibrillation, **47** and **49**, respectively. Conversely, the presence of a phenyl group at C2 resulted in potent compounds in both the 5,7,8-trimethyl-1,4-benzoxazine and the 5,7,8-trimethyl-benzopyran series. This effect was more pronounced within the 1,4-benzoxazine analogues because all 2-phenyl substituted derivatives **50**–**53** resulted in very good recovery of the heart after ischemia–reperfusion. The trolox-inspired-1,4-benzoxazinic derivative **62**, reduced reperfusion arrhythmias, and resulted in an extremely low MDA level, even lower than the nonperfused heart. We cannot give a reasonable explanation for this result based on the biological experiments performed so far.

The presence of a C6-chloro-substituent in 5,7,8-trimethyl-1,4-benzoxazines did not affect the antioxidant capacity and the arrhythmia score with respect to the nonchlorinated congeners, but it resulted in differences on the action potential parameters. A possible explanation could be differences in membrane binding and permeation due to halogenation, as previously reported.⁵⁰

As a general observation, the 5,7,8-trimethyl-1,4-benzoxazine scaffold resulted in more potent antiarrhythmic compounds when compared to the 5,7,8-trimethyl-benzopyran-substituted derivatives. This is not unexpected because the 2*H*-1,4-benzoxazine-3-(4*H*)-one and 3,4-dihydro-2*H*-1,4-benzoxazine systems have been studied extensively for building natural and designed biologically active compounds, which span from herbicides, fungicides, cardiovascular agents, K_{ATP} channel openers, compounds against diabetes, neuroprotectants, and agents against anxiety and depression.^{51–53} Thus, the above-mentioned heterocycles can be considered as privileged scaffolds for the development of potential new drugs. To the best of our knowledge, the 5,7,8-trimethyl-1,4-benzoxazine moiety has not been utilized yet as a template for the design of new antiarrhythmics. The presence of the three methyl substituents renders the system so electron rich that the corresponding 6-hydroxy-2-alkyl- or 6-hydroxy-2-aryl-5,7,8-trimethyl-1,4-benzoxazines were not stable⁵⁴ in contrast to the 6-methoxy-derivative **52**.

Concerning the effect of the new analogues on action potential parameters, we cannot draw specific structure–activity relationships, however it is evident that the compounds that suppressed reperfusion arrhythmias and did not induce ventricular tachycardia and/or ventricular fibrillation possess a multichannel profile. In addition, we cannot deduce any clear trend between MDA reduction and suppression of reperfusion arrhythmias for the compounds tested. It is possible that our compounds affect pathways of ischemia–reperfusion injury, which are not reflected on the MDA produced. However, the analogues that effectively suppressed reperfusion arrhythmias reduced MDA levels with respect to the control.

In conclusion, we have synthesized 5,7,8-trimethylbenzopyran and 5,7,8-trimethyl-1,4-benzoxazine derivatives encompassing the pharmacophore aminoamide functionality of lidocaine. On




Figure 4. (A) Arrangement of the intracellular action potential measurement. A fine glass sharp tip microelectrode was inserted into the intracellular space and the other (reference) electrode was placed at the extracellular environment. The potential difference between the two electrodes was measured through an amplifier and represents the electrical activity of the ventricular papillary muscle cells. (B) Body surface electrocardiogram (ECG), which represents the electrical activity of the whole heart and commonly used in the clinical practice. (C) Illustration of the relation between the intracellular action potential and the ECG recordings. The ECG signal represents the average of the large number of action potentials produced by the individual myocardial cells measured at the body surface. The P wave corresponds to the activity of the atrial cells, the QRS and T waves the depolarization and the repolarization of the ventricular myocytes, respectively. Therefore, as the figure shows changes of the maximal rate of depolarization (V_{max}) would result changes in the QRS waves and changes in the ventricular action potential duration would result changes in the QT interval.

Table 3. Effect of Compounds **46**, **47**, **49**, **50**, **62**, and **63** and Reference Drugs Sotalol and Mexiletine on the Action Potential Parameters in Rabbit Right Ventricular Papillary Muscle at 1 Hz Stimulation Frequency

compd ^a	RMP, ^e mV	APA, ^f mV	APD ₅₀ , ^g ms	APD ₉₀ , ^g ms	V_{max} , ^h V/s
46 ^b	-85.8 ± 0.3	111.9 ± 1.9	192.3 ± 7.5	236.8 ± 6.5	200.2 ± 18.2
control ^b	-86.5 ± 0.9	111.6 ± 1.7	160.7 ± 10.7	205.3 ± 9.1	220.2 ± 15.2
47	-85.9 ± 1.0	108.4 ± 2.8	147.1 ± 11.7	179.5 ± 10.1	175.4 ± 25.8
control	-87.4 ± 0.4	111.3 ± 0.9	145.1 ± 9.7	178.6 ± 9.3	275.4 ± 20.8
49	-85.3 ± 2.0	116.2 ± 1.7	171.6 ± 3.5	214.4 ± 3.5	188.4 ± 14.5
control	-84.0 ± 2.5	115.4 ± 2.1	155.8 ± 7.7	195.4 ± 7.6	197.0 ± 9.3
50	-82.7 ± 3.4	115.1 ± 3.1	175.6 ± 12.9	210.9 ± 12.4	174.5 ± 15.4
control	-84.4 ± 2.3	114.4 ± 2.6	149.8 ± 7.0	185.9 ± 5.2	203.3 ± 15.2
62	-86.6 ± 0.7	110.9 ± 3.1	161.7 ± 19.6	201.2 ± 18.5	171.9 ± 15.8
control	-85.2 ± 1.0	109.5 ± 2.0	144.6 ± 11.9	182.5 ± 10.6	193.5 ± 8.7
63	-81.5 ± 3.4	105.1 ± 4.2	107.7 ± 11.8	159.5 ± 5.0	184.7 ± 8.7
control	-83.7 ± 2.1	109.8 ± 0.9	110.0 ± 11.7	161.7 ± 5.3	251.7 ± 25.9
sotalol ^c	-85.9 ± 1.8	109.5 ± 2.1	219.9 ± 23.3	275.0 ± 24.8	202.4 ± 18.6
control	-87.9 ± 1.7	109.8 ± 1.7	153.8 ± 11.1	198.6 ± 10.7	220.2 ± 21.9
mexiletine ^d	-85.7 ± 2.0	105.9 ± 2.9	141.0 ± 10.6	180.9 ± 10.6	190.3 ± 19.7
control	-83.6 ± 0.9	106.2 ± 1.3	139.7 ± 8.5	179.6 ± 8.7	200.7 ± 9.5

^a $n = 3$. ^b $n = 4$. ^c $n = 7$ (reference compound). ^d $n = 10$ (reference compound). ^e RMP = resting membrane potential. ^f APA = action potential amplitude. ^g APD₅₀, APD₉₀ = action potential duration measured at 50% and 90% repolarization, respectively. ^h V_{max} = maximal rate of depolarization.

the basis of the evaluation of the antiarrhythmic and antioxidant properties as well as the cellular cardiac electrophysiological properties of the studied analogues **50** and **62** are promising compounds for further studies because of their multichannel "amiodarone like" effect, less proarrhythmic complications can be expected than with **47**, **63**, **46**, and **49**, which seem to have either class I or class III actions, which were responsible to the increased mortality in the CAST² and SWORD⁵⁵ multicenter clinical trials. However, it has to be emphasized that further studies are needed to establish the exact mode of action of the studied compounds because several possible potential antiarrhythmic mechanisms like calcium, ATP, acetylcholine ultra

rapid delayed rectifier (I_{Kur} kV 1.5) channel, or β receptor block can not be ruled out.

Experimental Section

NMR spectra were recorded on a Bruker AC 300 spectrometer operating at 300 MHz for ¹H and 75.43 MHz for ¹³C. ¹H NMR spectra are reported in units of δ relative to the internal standard of signals of the remaining protons of deuterated chloroform, at 7.24 ppm. ¹³C NMR shifts are expressed in units of δ relative to CDCl₃ at 77.0 ppm. ¹³C NMR spectra were proton noise decoupled. All NMR spectra were recorded in CDCl₃. Silica gel plates Macherey-Nagel Sil G-25 UV₂₅₄ were used for thin layer chromatography. Chromatographic purification was performed with silica




Figure 5. Frequency dependent effect of compounds **49**, **50**, and **62** on the conduction time (CT), maximal rate of depolarization (V_{max}), and action potential duration (APD90) on rabbit ventricular papillary muscles.

gel (200–400 mesh). Elemental analyses were carried out on a Perkin-Elmer series II CHNS/O 2400 analyzer. Mass spectra were recorded on a Varian Saturn 2000 GC-MS instrument in the EI mode.

2,3-Dihydro-2-phenyl-6-hydroxy-2,5,7,8-tetramethyl-4H-1-benzopyran-4-one (3). 2,4,5-Trimethyl-3,6-dihydroxyacetophenone (1.94 g, 10 mmol) and benzaldehyde (1.04 mL, 10 mmol) were added to a mixture of H_3BO_3 (0.927 g, 15 mmol), piperidine (0.25 mL, 2.5 mmol), and SiO_2 (2.5 g) in DMF (20 mL). The mixture was stirred at 120 °C overnight, and then it was cooled to room temperature and was diluted with acetone and filtered. The filtrate was evaporated in vacuo to afford benzopyranone **3** as viscous oil (0.9 g, 34%), which was used without further purification in the next step. 1H NMR (δ) 7.5–7.34 (m, 5H), 5.41 (d, $J = 12.8$ Hz, 1H), 3.05–2.84 (m, 2H), 2.47 (s, 3H), 2.21 (s, 3H), 2.13 (s, 3H). ^{13}C NMR (δ) 193.5, 158.3, 142.5, 139.3, 137.2, 129.7, 128.7, 128.4, 125.8, 124.4, 117.6, 78.5, 20.4, 14.1, 14.0, 12.2.

2,3-Dihydro-2-phenyl-6-hydroxy-5,7,8-trimethyl-4H-1-benzopyran-4-one-oxime (6). Oxime **6** was prepared according to the procedure described for oxime **4** using benzopyranone **3**, dry pyridine (5 mL), and hydroxylamine hydrochloride (0.963 g, 13.9 mmol) 0.21 g, 92% yield. 1H NMR (δ) 7.52–7.32 (m, 5H), 4.95 (dd, $J = 12.8$ Hz, $J = 3.7$ Hz, 1H), 3.50 (dd, $J = 17.7$ Hz, $J = 3.7$ Hz, 1H), 2.90 (dd, $J = 17.7$ Hz, $J = 12.2$ Hz, 1H), 2.50 (s, 3H), 2.22 (s, 3H), 2.19 (s, 3H). ^{13}C NMR (δ) 153.6, 150.2, 146.8, 140.6, 128.5, 127.9, 125.9, 125.8, 123.7, 118.5, 115.9, 77.2, 32.9, 14.7, 12.7, 12.1.

4-Amino-3,4-dihydro-2-phenyl-5,7,8-trimethyl-2H-1-benzopyran-6-ol (9). To a solution of $TiCl_4$ (0.17 mL, 1.53 mmol) in dimethoxyethane (2 mL) at 0 °C was added $NaBH_4$ (116 mg, 3.06 mmol). The mixture was stirred at 0 °C for 10 min, and subsequently a solution of oxime **6** (0.15 g, 0.51 mmol) in 2 mL




Figure 6. Frequency dependent effect of compounds **46**, **47**, and **63** and reference drugs sotalol and mexiletine on the conduction time (CT), maximal rate of depolarization (V_{max}), and action potential duration (APD90) on rabbit ventricular papillary muscles.

dimethoxyethane was added dropwise. The mixture was stirred at room temperature overnight. The reaction mixture was cooled to 0 °C and water was added. The mixture was made basic with the addition of 28% aqueous ammonia and was extracted with dichloromethane. The organic layer was extracted with brine, was dried (Na_2SO_4), and the solvent was evaporated in vacuo to afford **9**, which was used without further purification. Viscous oil, 0.121 g, yield: 84%. 1H NMR (δ) 7.46–7.29 (m, 5H), 5.26–4.95 (m, 1H), 4.07–4.16 (m, 1H), 2.24–2.12 (m, 11H).

N-(3,4-Dihydro-2-phenyl-6-hydroxy-5,7,8-trimethyl-2H-1-benzopyran-4-yl)-bromoacetamide (12). To a solution of 4-amino-3,4-dihydro-2-phenyl-5,7,8-trimethyl-2H-1-benzopyran-6-ol (**9**) (85

mg, 0.30 mmol) in a mixture of THF/H₂O 3/2 at 0 °C was added NaHCO₃ followed by the dropwise addition of bromoacetylchloride (0.60–1.2 mmol) until completion of the reaction by TLC. The reaction mixture was diluted with dichloromethane, and the organic layer was washed with saturated aqueous NaHCO₃, brine, and was dried over Na₂SO₄. The solvent was evaporated in vacuo to afford the desired bromoacetamide **12**, which was used without further purification. Viscous oil, 0.295 g, 73% yield. ¹H NMR (δ) 7.54–7.30 (m, 5H), 5.23–4.91 (m, 1H), 4.11–4.32 (m, 1H), 3.92–3.49 (m, 2H), 2.25–1.99 (m, 11H).

N-(3,4-Dihydro-2-phenyl-6-hydroxy-5,7,8-trimethyl-2H-1-benzopyran-4-yl)-(diethylamino)acetamide (15). To a solution of *N*-(3,4-dihydro-2-phenyl-6-hydroxy-5,7,8-trimethyl-2H-1-benzopyran-4-yl)-bromoacetamide (**12**) (113 mg, 0.28 mmol) in 7 mL toluene at 0 °C was added diethylamine (0.07 mL, 0.70 mmol). After stirring for 2 days at room temperature, the mixture was extracted with 2 N HCl. The aqueous layer was made basic with 2 N NaOH and extracted with CH₂Cl₂. The organic layer was dried (Na₂SO₄) and the solvent was evaporated in vacuo. Purification of the residue by flash column chromatography using dichloromethane/methanol 98:2 as elution solvent, compound **15** was obtained as a gummy solid (0.086 g, 78%). ¹H NMR (δ) 7.41–7.29 (m, 5H), 5.40–4.89 (m, 1H), 4.32–4.11 (m, 1H), 3.64–1.98 (m, 17H), 1.04–0.85 (m, 6H). ¹³C NMR (δ) 173.8, 150.1, 146.5, 140.8, 128.3, 127.6, 125.2, 125.1, 123.9, 118.7, 115.6, 77.1, 59.9, 48.5, 41.1, 39.8, 14.5, 12.5, 12.2, 11.8. Anal. (C₂₄H₃₂N₂O₃) C, H, N.

2-Nitro-3,5,6-trimethylphenol (17). A solution containing 2,3,5-trimethylphenol (**16**) (6.0 g, 44 mmol) in diethyl ether (100 mL) was added dropwise to a solution of sodium nitrate (3.71 g, 44 mmol) and La(NO₃)₃·6H₂O (0.191 g, 0.44 mmol) in 6 N HCl (72 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h and was then extracted with ethyl acetate. The organic layer was washed with brine, dried (Na₂SO₄), and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography (petroleum ether 40–60 °C/acetone 95:5) to afford 2-nitro-3,5,6-trimethylphenol as yellow solid (5.19 g, 65% yield): mp 74–77 °C. ¹H NMR (δ) 11.02 (s, 1H), 6.62 (s, 1H), 2.55 (s, 3H), 2.27 (s, 3H), 2.18 (s, 3H). ¹³C NMR (δ) 153.8, 145.4, 133.2, 132.9, 125.1, 124.4, 124.2, 22.5, 20.5, 11.6. MS (EI), *m/z*: 181 (100, M⁺). Anal. (C₉H₁₁NO₃) C, H, N.

2-Methyl-2-(2,3,5-trimethyl-6-nitrophenoxy)propanoic Acid Ethyl Ester (19). To a solution of 2-nitro-3,5,6-trimethylphenol (**17**) (0.4 g, 2.21 mmol) in dry DMF (7.35 mL) was added cesium carbonate (2.16 g, 6.62 mmol), TBAI (catalytic amount), and 2-bromo-2-methyl-propionic acid ethyl ester (0.97 mL, 6.62 mmol) and the mixture was heated at 60 °C for three days. Subsequently, the reaction the mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and dried (Na₂SO₄). The solvent was evaporated in vacuo, and the crude product was purified by flash column chromatography (petroleum ether 40–60 °C/acetone (95:5)) to afford compound **19** as a viscous oil, 0.487 g, 83% yield. ¹H NMR (δ) 6.78 (s, 1H), 4.19 (q, *J* = 7.1 Hz, 2H), 2.18 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 1.40 (s, 6H), 1.28 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (δ) 173.3, 144.8, 139.7, 131.0, 127.8, 127.7, 126.8, 83.2, 61.6, 24.7, 20.3, 16.6, 13.9, 13.6. Anal. (C₁₅H₂₁NO₅) C, H, N.

2,2,5,7,8-Pentamethyl-2H-1,4-benzoxazin-3(4H)-one (21). To a solution of 2-methyl-2-(2,3,5-trimethyl-6-nitrophenoxy)propanoic acid ethyl ester (**19**) (0.45 g, 1.52 mmol) in dry ethanol (18.7 mL) was added 10% palladium on carbon (0.112 mg). The suspension was stirred under 1 atm of hydrogen gas at 70 °C for 24 h. The reaction mixture was filtered through celite, the filtrate was concentrated in vacuo, and the crude product was purified by flash column chromatography (petroleum ether 40–60 °C/acetone (9:1)) to afford compound **21** as a white solid, 0.283 g, 85% yield: mp 166–170 °C. ¹H NMR (δ) 9.00 (s, 1H), 6.60 (s, 1H), 2.22 (s, 3H), 2.18 (s, 3H), 2.11 (s, 3H), 1.51 (s, 6H). ¹³C NMR (δ) 170.1, 140.4, 132.0, 124.5, 123.2, 122.8, 119.5, 77.3, 23.5, 19.4, 15.9, 11.3. MS, *m/z*: 219 (100, M⁺). Anal. (C₁₃H₁₇NO₂) C, H, N.

6-Chloro-2,2,5,7,8-pentamethyl-2H-1,4-benzoxazin-3(4H)-one (23). To a slurry of 2,2,5,7,8-pentamethyl-2H-1,4-benzoxazin-3(4H)-one (**21**) (0.13 g, 0.59 mmol) in petroleum ether (10.5 mL) was added a mixture of AcOH/H₂O₂ (30%)/HCl (37%) (0.22 mL, 3.85 mmol/ 0.43 mL, 3.85 mmol/0.15 mL, 1.48 mmol) and the resulting mixture was refluxed for 48 h. The reaction was diluted with ethyl acetate and the organic layer was extracted with water, saturated aqueous NaHCO₃, brine, and was dried (Na₂SO₄). The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (petroleum ether 40–60 °C/ethyl acetate (9:1)), to afford compound **23** as a white solid, 0.147 g, 98% yield; mp 234–237 °C. ¹H NMR (δ) 8.33 (s, 1H), 2.29 (s, 6H), 2.17 (s, 3H), 1.49 (s, 6H). ¹³C NMR (δ): 170.4, 138.9, 130.1, 127.9, 124.5, 123.7, 118.4, 77.19, 23.3, 17.0, 13.9, 12.4. MS, *m/z*: 253 (100, M⁺), 255 (36). Anal. (C₁₃H₁₆ClNO₂) C, H, N.

2-(2,3,5-Trimethyl-6-nitrophenoxy)-2-phenylacetic Acid Methyl Ester (24). Following the procedure for **19**, using 2-nitro-3,5,6-trimethylphenol (**17**) (0.4 g, 2.21 mmol), cesium carbonate (1.08 g, 3.31 mmol), bromophenylacetic acid methyl ester (0.758 g, 3.31 mmol), and stirring at room temperature for 5 min, compound **24** was obtained after purification by flash column chromatography (petroleum ether 40–60 °C/ethyl acetate (95:5)). Gummy solid, 0.88 g, 97% yield. ¹H NMR (δ) 7.45–7.33 (m, 5H), 6.85 (s, 1H), 5.29 (s, 1H), 3.69 (s, 3H), 2.18 (s, 3H), 2.17 (s, 3H), 1.93 (s, 3H). ¹³C NMR (δ) 169.7, 147.5, 144.3, 140.9, 135.2, 129.3, 128.7, 127.9, 127.8, 127.5, 84.6, 52.5, 20.2, 17.0, 13.2. Anal. (C₁₈H₁₉NO₅) C, H, N.

2-Phenyl-5,7,8-trimethyl-2H-1,4-benzoxazin-3(4H)-one (25). To a solution of 2-(2,3,5-trimethyl-6-nitrophenoxy)-2-phenylacetic acid methyl ester (**24**) (0.800 g, 2.43 mmol) in absolute ethanol (12.1 mL) at 0 °C was added CuCl (1.202 g, 12.15 mmol) followed by NaBH₄ (0.918 g, 24.3 mmol) over 5 min. The resulting mixture was refluxed for 15 min, and the reaction was cooled to room temperature. Water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄, and the solvent was evaporated in vacuo. The crude product was purified by flash column chromatography (petroleum ether 40–60 °C/acetone (9:1)) to afford compound **25** as white crystals, 0.5 g, 77% yield; mp 171–173 °C. ¹H NMR (δ) 9.23 (s, 1H), 7.33–7.48 (m, 5H), 6.61 (s, 1H), 5.72 (s, 1H), 2.21 (s, 9H). ¹³C NMR (δ) 166.3, 140.9, 135.5, 132.3, 128.5, 126.6, 125.1, 122.6, 122.2, 120.9, 78.0, 19.4, 16.2, 11.6; MS, *m/z*: 267 (10, M⁺), 207 (100).

2-Phenyl-5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine (36). To a solution of 2-phenyl-5,7,8-trimethyl-2H-1,4-benzoxazin-3(4H)-one (**25**) (0.2 g, 0.75 mmol) in THF (35 mL) was added dropwise at 0 °C a solution of boron trifluoride etherate (2.24 mmol, 0.28 mL). The reaction mixture was stirred at 0 °C for 20 min, and subsequently NaBH₄ (85 mg, 2.24 mmol) was added over 10 min. The resulting mixture was stirred at room temperature overnight and was diluted with ethyl acetate. The organic layer was extracted with saturated aqueous NaHCO₃ and brine and was dried (Na₂SO₄). The solvent was evaporated in vacuo, and the residue was purified by flash column chromatography (petroleum ether 40–60 °C/ethyl acetate (9:1)), to afford benzoxazine **36** as white crystals, 0.186 g, 98% yield; mp 80–82 °C. ¹H NMR (δ) 7.50–7.34 (m, 5H), 6.59 (s, 1H), 5.10 (dd, *J* = 8.5 Hz, 2.4 Hz, 1H), 3.61 (d, *J* = 11.6 Hz, 1H), 3.36–3.29 (m, 1H), 2.23 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H). ¹³C NMR (δ) 142.5, 139.7, 128.5, 128.4, 128.0, 126.8, 129.1, 123.3, 122.4, 120.4, 75.5, 48.2, 19.2, 16.6, 11.5. MS, *m/z*: 253 (100, M⁺). Anal. (C₁₇H₁₉NO) C, H, N.

2-Bromo-1-(5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (43). To a solution of 2-phenyl-5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine (**36**) (150 mg, 0.59 mmol) in dry dichloromethane (12 mL) was added dropwise at 0 °C triethylamine (0.17 mL, 1.18 mmol) and bromoacetyl bromide (0.08 mL, 0.89 mmol). The resulting mixture was stirred at room temperature for 30 min and then diluted with saturated aqueous NaHCO₃ and extracted with ethyl acetate. The organic phase was washed with saturated aqueous NaCl and was dried (Na₂SO₄). The solvent was evaporated in vacuo, and the crude residue was purified by flash

column chromatography (petroleum ether 40–60 °C/ethyl acetate (9:1)) to afford compound **43** as a yellowish solid, 0.174 g, 79% yield; mp 109–111 °C. Two rotamers of compound **43** were detected in the NMR spectra, and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 7.47–7.00 (m, 5H), 6.69 (bs, 1H), 5.73–4.88 (m, 2H), 4.64–2.78 (m, 3H), 2.28–2.10 (m, 9H). ¹³C NMR (δ) 167.9, 147.3, 138.1, 136.6, 135.9*, 128.8, 128.7, 128.6, 128.5*, 125.9, 125.6*, 125.5*, 123.9, 123.8*, 122.8, 78.1, 51.6*, 48.6, 27.1, 26.3*, 19.9, 19.8*, 17.2, 11.7.

Diethylamino-1-(5,7,8-trimethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (46). Following the procedure for compound **15** using 2-bromo-1-(5,7,8-trimethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**39**) (83 mg, 0.28 mmol), compound **46** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (95:5)). Viscous oil, 77 mg, 95% yield. Two rotamers of compound **46** were detected in the NMR spectra and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 6.59* and 6.58 (1H), 4.90* (ddd, *J* = 13.4 Hz, 4.3 Hz, 1.2 Hz, 0.6H) and 4.65 (d, *J* = 14.7 Hz, 0.4H), 4.49–4.19 (m, 2H), 3.49–3.09 (m, 2H and 0.4H), 2.80* (ddd, *J* = 13.4 Hz, 4.3 Hz, 4.3 Hz, 0.6H), 2.65–2.48 (m, 4H), 2.20–2.04 (m, 9H), 1.05 (t, *J* = 7.0 Hz, 2.4H), 0.89* (t, *J* = 7.0 Hz, 3.6H). ¹³C NMR (δ) 171.9, 168.9*, 146.9, 146.2*, 135.8, 135.1*, 131.3*, 129.3, 124.8, 123.5*, 123.3, 122.9*, 122.3, 121.5*, 67.5*, 67.2, 57.8, 53.0*, 47.6, 47.2*, 44.0*, 41.7, 19.8, 19.7*, 18.8*, 17.3, 12.1*, 11.5. MS (ESI) *m/z* 291.3 ([*M* + 1]⁺, 100). HRMS (FAB⁺) calcd for C₁₇H₂₇O₂N₂ [*M* + 1]⁺ 291.2073, found 291.2087. Anal. (C₁₇H₂₆N₂O₂) C, H, N.

2-Diethylamino-1-(2,2,5,7,8-pentamethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (47). Following the procedure for compound **15** using 2-bromo-1-(2,2,5,7,8-pentamethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**40**) (90 mg, 0.28 mmol), compound **47** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (96:4)). Viscous oil, 85 mg, 95% yield. Two rotamers of compound **47** were detected in the NMR spectra and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 6.62* (s, 0.5H), 6.58 (s, 0.5H), 4.88* (d, *J* = 12.8 Hz, 0.5 H), 4.45 (d, *J* = 14.0 Hz, 0.5H), 3.73–3.15 (m, 2H and 0.5H), 2.83–2.65 (m, 4H), 2.59* (d, *J* = 12.8 Hz, 0.5 H), 2.21–2.04 (m, 9H), 1.40–1.24 (m, 6H), 1.11 (t, *J* = 7.0 Hz, 3H), 1.00 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (δ) 169.8, 168.9*, 148.3, 146.2*, 136.0, 134.9*, 130.5, 128.5*, 125.2, 123.8, 123.3*, 123.1*, 121.8, 121.6*, 80.1, 76.2*, 52.9, 52.1*, 47.7, 47.5*, 27.5, 27.1*, 26.6, 25.0*, 19.7, 19.6, 19.3, 17.4, 11.7, 11.4. MS (ESI) *m/z* 319.4 ([*M* + 1]⁺, 100). HRMS (FAB⁺) calcd for C₁₉H₃₁O₂N₂ [*M* + 1]⁺ 319.2386, found 319.2380. Anal. (C₁₉H₃₀N₂O₂) C, H, N.

1-(6-Chloro-5,7,8-trimethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-diethylamino-ethanone (48). Following the procedure for compound **15** using 2-bromo-1-(6-chloro-5,7,8-trimethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**41**) (93 mg, 0.28 mmol), compound **48** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (98:2)). Viscous oil, 90 mg, quantitative yield. Two rotamers of compound **48** were detected in the NMR spectra and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 4.90* (dd, *J* = 13.4 Hz, 4.3 Hz, 0.6 H), 4.64 (dd, *J* = 13.7 Hz, 2.7 Hz, 0.4H), 4.56–4.17 (m, 2H), 3.44–3.08 (m, 2H, and 0.4H), 2.78* (ddd, *J* = 12.2 Hz, 4.3 Hz, 4.3 Hz, 0.6H), 2.65–2.43 (m, 4H), 2.30 (s, 1.8H), 2.27 (s, 1.2H), 2.23 (s, 1.8H), 2.14 (s, 1.8H), 2.10 (s, 1.2H), 2.09 (s, 1.2H), 1.04 (t, *J* = 7.0 Hz, 2.4H), 0.87* (t, *J* = 7.0 Hz, 3.6H). ¹³C NMR (δ) 172.2, 169.2*, 145.4, 144.8*, 133.9, 133.3*, 129.8, 128.2, 126.7, 126.4*, 125.5, 123.7, 123.5*, 122.9, 67.5, 67.1*, 57.6*, 53.5, 47.6, 47.2*, 43.9, 41.6, 17.3, 17.1, 16.7, 12.5, 12.2, 12.1, 11.4. MS (ESI) *m/z* 325.3 ([*M* + 1]⁺, 100), 327.3 ([*M* + 3]⁺, 39). HRMS (FAB⁺) calcd for C₁₇H₂₆O₂N₂Cl [*M* + 1]⁺ 325.1683, found 325.1686. Anal. (C₁₇H₂₅ClN₂O₂) C, H, N.

1-(6-Chloro-2,2,5,7,8-pentamethyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-diethylamino-ethanone (49). Following the procedure for compound **15** using 2-bromo-1-(6-chloro-2,2,5,7,8-pentamethyl-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethanone (**42**) (103 mg, 0.28 mmol),

compound **49** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (96:4)). Viscous oil, 92 mg, 93% yield. Two rotamers of compound **49** were detected in the NMR spectra, and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 4.91* (d, *J* = 12.8 Hz, 0.6 H), 4.55 (d, *J* = 14.0 Hz, 0.4H), 3.63 (d, *J* = 14.6 Hz, 0.4H), 3.37–3.10 (m, 2H), 2.83–2.54 (m, 4H and 0.6H), 2.32–2.10 (m, 9H), 1.40–1.24 (m, 6H), 1.08 (t, *J* = 7.3 Hz, 2.4H), 0.92* (t, *J* = 7.0 Hz, 3.6H). ¹³C NMR (δ) 171.1, 170.0*, 146.8, 144.9*, 133.8, 133.0*, 129.1, 127.6*, 126.9, 126.2*, 126.1, 124.5*, 123.1, 122.5*, 80.4, 76.5*, 57.3, 53.5*, 52.9, 51.8*, 47.4, 27.3, 27.0, 26.5, 25.1, 17.7, 17.1, 16.9, 12.5, 12.3, 12.2, 11.8. MS (ESI) *m/z* 353.3 ([*M* + 1]⁺, 100), 355.3 ([*M* + 3]⁺, 37). HRMS (FAB⁺) calcd for C₁₉H₃₀O₂N₂Cl [*M* + 1]⁺ 353.1996, found 353.2001. Anal. (C₁₉H₂₉ClN₂O₂) C, H, N.

2-Diethylamino-1-(5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (50). Following the procedure for compound **15** using 2-bromo-1-(5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**43**) (104 mg, 0.28 mmol), compound **50** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (98:2)). Viscous oil, 98 mg, 95% yield. Two rotamers of compound **50** were detected in the NMR spectra and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 7.43–7.23 (m, 5H), 6.67 (bs, 1H), 5.67–4.78 (m, 2H), 3.72–2.43 (m, 7H), 2.27–2.08 (m, 9H), 1.11–0.83 (m, 6H). ¹³C NMR (δ) 172.3, 168.5*, 147.2, 146.6*, 140.8*, 138.7, 136.0, 135.3*, 131.3, 129.3*, 128.7, 128.6, 128.3, 125.8, 125.7, 124.7, 123.6, 123.5*, 122.5, 122.4*, 121.7, 79.2*, 79.0, 58.2, 53.2, 50.6, 48.4, 47.7, 47.5, 47.3*, 19.8, 19.7*, 18.9, 17.4, 12.2, 11.9*, 11.7, 11.4*. MS (ESI) *m/z* 367.4 ([*M* + 1]⁺, 100); HRMS (FAB⁺) calcd for C₂₃H₃₁O₂N₂ [*M* + 1]⁺ 367.2386, found 367.2370. Anal. (C₂₃H₃₀N₂O₂) C, H, N.

1-(6-Chloro-5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-diethylamino-ethanone (51). Following the procedure for compound **15** using 2-bromo-1-(6-chloro-5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**44**) (114 mg, 0.28 mmol), compound **51** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (98:2)). Viscous oil, 109 mg, 97% yield. Two rotamers of compound **51** were detected in the NMR spectra and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 7.41–7.21 (m, 5H), 5.67–4.80 (m, 2H), 3.71–2.03 (m, 16H), 1.13–0.82 (m, 6H). ¹³C NMR (δ) 172.4, 170.3, 168.7, 145.8, 145.5, 145.3, 140.6, 138.4, 134.1, 133.5, 133.3, 129.9, 129.7, 128.7, 128.6, 128.4, 127.0, 126.7, 125.8, 125.7, 125.4, 124.2, 123.8, 123.2, 123.0, 122.8, 79.3, 79.0*, 58.0, 56.5, 53.6, 50.5, 48.9, 48.3*, 47.6, 47.5, 47.3, 17.5, 17.2, 16.9, 12.7, 12.3, 11.9, 11.3. MS (ESI) *m/z* 401.3 ([*M* + 1]⁺, 100), 403.4 ([*M* + 3]⁺, 37). HRMS (FAB⁺) calcd for C₂₃H₃₀O₂N₂Cl [*M* + 1]⁺ 401.1996, found 401.1968. Anal. (C₂₃H₂₉ClN₂O₂) C, H, N.

1-(6-Methoxy-5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-diethylamino-ethanone (52). Following the procedure for compound **15** using 2-bromo-1-(6-methoxy-5,7,8-trimethyl-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)-ethanone (**45**) (120 mg, 0.28 mmol), compound **52** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/methanol (98:2)). Viscous oil, 0.105 g, 95% yield; Two rotamers of compound **52** were detected in the NMR spectra, and the corresponding peaks are defined by an asterisk. ¹H NMR (δ) 7.43–7.21 (m, 5H), 5.65–4.75 (m, 2H), 3.69 (s, 3H), 3.68–2.38 (m, 7H), 2.28–2.04 (m, 9H), 1.12–0.82 (m, 6H). ¹³C NMR (δ) 172.3*, 168.4, 150.5*, 150.0, 143.8*, 143.1, 138.7, 129.1, 128.7, 128.5, 128.2, 125.8, 125.7, 124.8, 124.6, 123.3, 122.9, 122.8, 122.5, 122.1, 79.0, 78.9*, 77.8*, 60.2, 58.1, 56.6, 53.3, 50.7, 49.1, 48.4, 47.5, 47.4, 47.2, 12.7, 12.5, 12.3, 12.1, 12.0, 11.3. MS (ESI) *m/z* 397.4 ([*M* + 1]⁺, 100). HRMS (FAB⁺) calcd for C₂₄H₃₃O₃N₂ [*M* + 1]⁺ 397.2491, found 397.2512. Anal. (C₂₄H₃₂N₂O₃) C, H, N.

2-(2,3,5-Trimethyl-6-nitrophenoxy)-2-methylmalonic Acid Diethyl Ester (53). Following the procedure for compound **19** using 2-nitro-3,5,6-trimethylphenol (**17**) (0.4 g, 2.21 mmol) in dry DMF (7.35 mL), cesium carbonate (1.44 g, 4.42 mmol), TBAI (catalytic

amount), and 2-bromo-2-methyl-malonic acid diethyl ester (0.84 mL, 4.42 mmol) after purification by flash column chromatography (petroleum ether 40–60 °C/diethyl ether (9:1)), we obtained compound **53** as a viscous oil 0.748 g, 96% yield. ¹H NMR (δ) 6.71 (s, 1H), 4.09 (q, *J* = 7.1 Hz, 4H), 2.05 (s, 3H), 1.97 (s, 3H), 1.93 (s, 3H), 1.32 (s, 3H), 1.12 (t, *J* = 7.3 Hz, 6H). ¹³C NMR (δ): 167.9, 145.8, 143.1, 139.9, 131.1, 128.2, 126.5, 84.4, 61.9, 19.6, 17.7, 17.6, 15.9, 13.4, 12.7. MS, *m/z*: 353 (8, M⁺), 205 (100). Anal. (C₁₇H₂₃NO₇) C, H, N.

2,5,7,8-Tetramethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic Acid Ethyl Ester (54). Following the procedure for compound **21** using 2-(2,3,5-trimethyl-6-nitrophenoxy)-2-methyl-malonic acid diethyl ester (**53**) (0.7 g, 1.98 mmol) and Pd/C (0.175 g) after purification by flash column chromatography (petroleum ether 40–60 °C/ethyl acetate (85:15)), we obtained compound **54** as white crystals, 0.444 g, 81% yield; mp 124–126 °C. ¹H NMR (δ) 8.15 (s, 1H), 6.62 (s, 1H), 4.20–4.03 (m, 2H), 2.19 (s, 3H), 2.18 (s, 3H), 2.17 (s, 3H), 1.85 (s, 3H), 1.13 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (δ) 168.9, 164.7, 141.2, 132.3, 125.5, 123.3, 122.3, 120.3, 80.5, 62.0, 20.5, 19.3, 15.9, 13.8, 11.4. MS, *m/z*: 277 (61, M⁺), 204 (100). Anal. (C₁₅H₁₉NO₄) C, H, N.

2,5,7,8-Tetramethyl-3-thioxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic Acid Ethyl Ester (56). A mixture of 2,5,7,8-tetramethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid ethyl ester (**54**) (0.2 g, 0.72 mmol), Lawesson's reagent (0.32 g, 0.79 mmol), and toluene (0.81 mL) was refluxed under inert atmosphere for 2 h. The resulting mixture was mixed with silica gel and the toluene was evaporated in vacuo. The silica gel cake was then added to a column of silica gel, and the column was eluted with petroleum ether 40–60 °C/ethyl acetate (85:15) to afford compound **56** as a green–yellow solid (0.205 g, yield: 97%); mp 114–116 °C. ¹H NMR (δ) 9.45 (s, 1H), 6.59 (s, 1H), 4.21–4.05 (m, 2H), 2.22 (s, 3H), 2.17 (s, 3H), 2.15 (s, 3H), 1.95 (s, 3H), 1.13 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (δ) 191.5, 168.6, 142.5, 134.4, 125.2, 123.4, 122.2, 119.5, 83.9, 62.2, 23.8, 19.6, 15.9, 13.8, 11.2. MS, *m/z*: 293 (10, M⁺), 220 (100). Anal. (C₁₅H₁₉NO₃S) C, H, N.

2,5,7,8-Tetramethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic Acid Ethyl Ester (58). To a solution of 2,5,7,8-tetramethyl-3-thioxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid ethyl ester (**56**) (0.2 g, 0.68 mmol) in tetrahydrofuran (1 mL) and ethanol (1 mL) was added Raney nickel and water (0.5 mL). After stirring for 5 min, an additional amount of catalyst was added and water (0.5 mL) and the reaction was stirred at room temperature for additional 15 min. The reaction mixture was diluted with ethyl acetate, it was filtered through celite, and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography (petroleum ether 40–60 °C/ethyl acetate (90:10) to afford compound **58** as white crystals (0.146 g, 82%); mp 84–87 °C. ¹H NMR (δ) 6.49 (s, 1H), 4.13 (q, *J* = 7.1 Hz, 2H), 3.75 (d, *J* = 11.6 Hz, 1H), 3.14 (d, *J* = 11.6 Hz, 1H), 2.16 (s, 3H), 2.15 (s, 3H), 2.05 (s, 3H), 1.56 (s, 3H), 1.17 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (δ) 172.5, 141.0, 127.7, 126.7, 123.4, 122.1, 120.2, 76.4, 61.2, 48.2, 22.6, 19.3, 16.4, 14.0, 11.4. MS, *m/z*: 263 (100, M⁺); Anal. (C₁₅H₂₁NO₃) C, H, N.

4-(2-Bromo-acetyl)-2,5,7,8-tetramethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic Acid Ethyl Ester (60). Following the procedure for compound **43** using 2,5,7,8-tetramethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid ethyl ester (**58**) (156 mg, 0.59 mmol), compound **60** was obtained after purification of the crude residue by flash column chromatography (petroleum ether 40–60 °C/dichloromethane/ethyl acetate (80:15/5)). Yellowish solid, 0.201 g, 89% yield; mp 112–114 °C. The NMR spectra contain multiple signals due to the presence of rotamers. ¹H NMR (δ) 6.69–6.63 (m, 1H), 5.22–4.48 (m, 1H), 4.19–3.75 (m, 4H), 2.22–2.13 (m, 9H), 1.71–1.60 (m, 3H), 1.32–1.14 (m, 3H). ¹³C NMR (δ) 172.8, 171.6, 167.5, 167.2, 165.5, 148.5, 146.4, 145.1, 136.9, 136.3, 135.2, 130.8, 128.7, 128.0, 126.2, 124.9, 124.2, 124.0, 122.8, 122.7, 121.6, 120.5, 82.1, 79.5, 78.9, 62.4, 62.2, 61.6, 50.9, 49.5, 49.1, 27.9, 27.0, 26.4, 24.3, 22.8, 22.3, 19.8, 19.6, 18.2, 17.3, 16.9, 14.0, 11.5, 11.4. Anal. (C₁₇H₂₂BrNO₄) C, H, N.

4-(2-Diethylamino-acetyl)-2,5,7,8-tetramethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic Acid Ethyl Ester (62). Following the procedure for compound **15** using 4-(2-bromo-acetyl)-2,5,7,8-tetramethyl-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid ethyl ester (**60**) (109 mg, 0.28 mmol), compound **62** was obtained after purification of the crude residue by flash column chromatography (dichloromethane/ethyl acetate (6:4)). Viscous oil, 85 mg, 81% yield. The NMR spectra contain multiple signals due to the presence of rotamers. ¹H NMR (δ) 6.68–6.61 (m, 1H), 5.32–5.06 (m, 1H), 4.21–4.02 (m, 2H), 3.74–2.41 (m, 7H), 2.22–2.03 (m, 9H), 1.69–1.55 (m, 3H), 1.33–0.89 (m, 9H). ¹³C NMR (δ): 173.0, 172.2, 172.0, 171.9, 171.6, 169.9, 148.7, 146.6, 145.3, 136.3, 135.8, 134.6, 130.5, 128.9, 128.7, 127.3, 124.9, 124.0, 123.9, 122.6, 121.7, 121.5, 82.4, 80.1, 79.2, 62.1, 61.7, 61.5, 57.7, 57.5, 53.6, 53.1, 50.3, 50.0, 49.4, 49.3, 47.6, 47.4, 24.7, 23.0, 22.9, 19.8, 19.6, 19.4, 17.5, 17.1, 14.0, 13.9, 12.3, 12.2, 11.8, 11.6, 11.5. MS (ESI) *m/z* 377.4 ([M + 1]⁺, 100). HRMS (FAB⁺) calcd for C₂₁H₃₃O₄N₂ [M + 1]⁺ 377.2440, found 377.2441. Anal. (C₂₁H₃₂N₂O₄) C, H, N.

Animals and Heart Preparations. Male Wistar rats weighing about 300–350 g were housed under controlled light (12 L/12D) and temperature with free access to food and water in compliance with the prescriptions for the care and use of laboratory animals. Rats were anesthetized with pentobarbital (30–40 mg per animal). After intravenous administration of heparin, the chests were opened and the hearts were rapidly excised and mounted on a nonrecirculating Langendorff perfusion apparatus. Retrograde perfusion was established at a pressure of 90 cm H₂O with an oxygenated normothermic Krebs–Henseleit bicarbonate (KHB) buffer (25 mmol l⁻¹ NaHCO₃, 118 mmol l⁻¹ NaCl, 2.5 mmol l⁻¹ CaCl₂, 4.7 mmol l⁻¹ KCl, 1.4 mmol l⁻¹ MgSO₄, 1.2 mmol l⁻¹ KH₂PO₄, pH 7.2 at 25 °C) supplemented with 11 mmol l⁻¹ glucose and equilibrated with 95% O₂/5% CO₂. The temperature of the hearts and perfusates was maintained at 37 °C by the use of a water-jacketed apparatus. All hearts were equilibrated for 20 min under these conditions. At the end of the equilibration period, hearts were made ischemic for 15 min by perfusing them with the ischemic KHB (KHB with Tris-HCl 10 mM instead of glucose and equilibrated with N₂ before use) followed by 60 min of reperfusion. The compounds were present during the last 5 min of ischemia and during reperfusion at a final concentration of 2 μM.

Evaluation of Antiarrhythmic Activity. Electrocardiograms were recorded during equilibration, ischemia, and reperfusion. Arrhythmia scores (AS) were calculated for the first 10 min of reperfusion according to the Lambeth Convention Guidelines.⁴¹

Evaluation of Antioxidant Activity. At the end of the perfusions, hearts were “freeze-clamped” between aluminum tongs, cooled in liquid N₂, and after the removal of the atria, the ventricles were pulverized under liquid N₂ and powders were stored at –80 °C. A portion of the tissue powder was analyzed for malondialdehyde (MDA) content by using the thiobarbituric acid assay.⁴³ To prevent auto-oxidation of the samples, homogenization was carried out at 4 °C in nitrogen equilibrated solution in the presence of 0.04% butylated hydroxytoluene, 1.6% ethanol. The values were expressed as nanomoles of TBA reactive substances (MDA equivalent) per gram of tissue. 1,1,3,3-Tetraethoxypropane (0,0.5,1.0,2.0,4.0,8.0 and 16.0 nmol) served as external standard. Results are expressed as mean ± SEM. Differences between groups were assessed by Student's unpaired and ANOVA *t* tests and considered significant when *p* < 0.05.

Conventional Microelectrode Technique. New Zealand rabbits weighing 1.5–2.0 kg of either sex were used. Each animal was sacrificed by cervical dislocation after an intravenous injection of 400 IU kg/L heparin. The chest was opened, the heart quickly removed, and immediately rinsed in oxygenated modified Locke's solution containing (in mM): NaCl, 120; KCl, 4; CaCl₂, 1.0; MgCl₂, 1; NaHCO₃, 22 and glucose, 11. The pH of this solution was 7.35 to 7.40 when saturated with 95% O₂ and 5% CO₂ at 37 °C. Tips of papillary muscles obtained from the right ventricle were individually mounted in a tissue chamber (volume ≈ 50 mL). Each ventricular preparation was initially stimulated at a basic cycle length of 1000 ms (frequency = 1 Hz), using rectangular constant current pulses

1 ms in duration. These stimuli were isolated from ground and delivered through a bipolar platinum electrode in contact with the preparation. Temperature of the superfusate was kept constant at 37 °C. Transmembrane potentials were recorded using conventional microelectrode techniques. Microelectrodes filled with 3 M KCl and having tip resistances of 5–20 MΩ were connected to the input of a high impedance electrometer (Experimetria). The voltage output of the amplifier was displayed on a memory oscilloscope (Tektronix 2230 100 MHz digital storage oscilloscope, Beaverton, OR) and fed into a computer (PC, Windows XP) at a sampling rate of 10 kHz. The stimulation triggering and data acquisition were governed by homemade (APES)/software. The resting membrane potential (RP), conduction time (CT), action potential amplitude (APA), maximal rate of depolarization (V_{max}), and action potential duration at 50 and 90% of (APD50/90) were automatically measured using the software and analyzed both online and off-line. In each experiment, baseline action potential characteristics were first determined during continuous pacing at 1 Hz, and then pacing cycle length was sequentially varied between 300 and 5000 ms. The 25th action potential was measured at each cycle length, and the cycle length was then changed so that “quasi” steady-state frequency response relations could be generated rapidly. At least 1 h was allowed for each preparation to equilibrate after mounting before experimental measurements were initiated.

Acknowledgment. This work was supported in part by the Greek General Secretariat for Research and Technology, “Excellence in the Research Institutes Supervised by the GSRT” EPAN 3.3.1. (2006–2009), by the Hungarian Academy of Sciences, and by grants from the Hungarian National Research Foundation (OTKA NI-61902) and the Hungarian Ministry of Health (ETT-360/2006).

Supporting Information Available: Experimental procedures and spectroscopic data for compounds **1**, **2**, **4**, **5**, **7**, **8**, **10**, **11**, **13**, **14**, **18**, **20**, **22**, **26–35**, **37–42**, **44**, **45**, **55**, **57**, **59**, **61**, **63–65**, **26b**, **37b**, and **51b**. Effect of compounds **46**, **47**, **49**, **50**, **62**, and **63** and reference drugs sotalol and mexiletine on the action potential in rabbit right ventricular papillary muscles (Figure A). Elemental analysis data for compounds **13–15**, **17–19**, **21–26**, **30**, **31**, **36–38**, and **44–63**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- Janse, M. J.; Wit, A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. *Physiol. Rev.* **1989**, *69*, 1049–1169.
- (a) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction. *N. Engl. J. Med.* **1989**, *321*, 406–412; (b) The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N. Engl. J. Med.*, **1992**, *327*, 227–233.
- Zareba, W. Implantable cardioverter defibrillator therapy in postinfarction patients. *Curr. Opin. Cardiol.* **2004**, *19*, 619–624.
- (a) Piper, H. M.; Garcia-Dorado, D.; Ovize, M. A. fresh look at reperfusion injury. *Cardiovasc. Res.* **1998**, *38*, 291–300. (b) Andreadou, I.; Iliodromitis, E. K.; Koufaki, M.; Farmakis, D.; Tsotinis, A.; Kremastinos, D. Th. Alternative Pharmacological Interventions that Limit Myocardial Infarction. *Curr. Med. Chem.* **2008**, *15*, 3204–3213.
- Ambrosio, G.; Tritto, I. Reperfusion injury: experimental evidence and clinical implications. *Am. Heart J.* **1999**, *138*, S69–S75.
- (a) Park, J. L.; Lucchesi, B. R. Mechanisms of myocardial reperfusion injury. *Ann. Thorac. Surg.* **1999**, *68*, 1905–1912. (b) Yellon, D. M.; Hausenloy, D. J. Myocardial Reperfusion Injury. *N. Engl. J. Med.* **2007**, *357*, 1121–1135.
- (a) Piper, H. M.; Meuter, K.; Schäfer, C. Cellular mechanisms of ischemia-reperfusion injury. *Ann. Thorac. Surg.* **2003**, *75*, S644–S648. (b) Woodcock, E. A. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. *Clin. Exp. Pharmacol. Physiol.* **2007**, *34*, 884–888. (c) Vasilevski, O.; Grubb, D. R.; Filtz, T. M.; Yang, S.; McLeod-Dryden, T. J.; Luo, J.; Karna, D.; Chen, J.; Woodcock, E. A. Ins(1,4,5)P₃ regulates phospholipase Cβ1 expression in cardiomyocytes. *J. Mol. Cell. Cardiol.* **2008**, *45*, 679–684.
- (a) Wang, Q. D.; Pernow, J.; Sjoquist, P. O.; Ryden, L. Pharmacological possibilities for protection against myocardial reperfusion injury. *Cardiovasc. Res.* **2002**, *55*, 25–37. (b) Grover, G. J.; Garlid, K. D. ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology. *J. Mol. Cell. Cardiol.* **2000**, *32*, 677–695.
- Parrat, J. R. Inhibitors of the slow calcium current and early ventricular arrhythmias In: Parrat, J. R., Ed.; *Early Arrhythmias Resulting from Myocardial Ischemia*; Macmillan: London, 1982, 329–346.
- He, Z. S.; Komori, S.; Tamura, K.; Hashimoto, K. Inhibitory effect of moricizine on reperfusion induced tachyarrhythmias in rats. A comparison study with disopyramide and mexiletine. *Jpn. Circ. J.* **1992**, *56*, 861–865.
- Corr, P. B.; Pogwizd, S. M. Mechanisms contributing to arrhythmogenesis during early myocardial ischemia, subsequent reperfusion, and chronic infarction. *Angiology* **1988**, *39*, 684–699.
- Komori, S.; Sano, S.; Li, B. H.; Matsumura, K.; Naitoh, A.; Mochizuki, S.; Ishihara, T.; Watanabe, A.; Umetani, K.; Iiiri, H.; Hashimoto, K.; Tamura, K. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. *Heart Vessel* **1995**, *10*, 7–11.
- Butwell, N. B.; Ramasamy, R.; Lazar, I.; Sherry, A. D.; Malloy, C. R. Effect of lidocaine on contracture, intracellular sodium and pH in ischemic rat hearts. *Am. J. Physiol.* **1993**, *264*, H1884–H1889.
- Tani, M.; Neely, J. R. Role of intracellular Na⁺ in Ca²⁺ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H⁺–Na⁺ exchange. *Circ. Res.* **1989**, *65*, 1045–1056.
- Pike, M. M.; Kitakaze, M.; Chacko, V. P.; Marban, E. Lidocaine prevents the increase in myocardial free calcium during ischemia and reperfusion: an antiarrhythmic mechanism. *Circulation* **1987**, *76*, IV-16.
- Saint, D. A. The cardiac persistent sodium current: an appealing therapeutic target? *Br. J. Pharmacol.* **2008**, *153*, 1133–1142.
- Arakawa, J.; Hara, A.; Kokita, N. Lidocaine attenuates mechanical and metabolic derangements induced by palmitoyl-L-carnitine in the isolated perfused rat heart. *Pharmacology* **1997**, *55*, 259–268.
- Das, D. K.; Misra, H. P. Lidocaine: a hydroxyl radical scavenger and singlet oxygen quencher. *Mol. Cell. Biochem.* **1992**, *115*, 179–185.
- Josephson, I. R. Lidocaine blocks Na, Ca, and K currents of chick ventricular myocytes. *J. Mol. Cell. Cardiol.* **1988**, *20*, 593–604.
- Sugiyama, K.; Muteki, T. Local anesthetics depress the calcium current of rat sensory neurons in culture. *Anesthesiology* **1994**, *80*, 1369–1378.
- Kojima, M.; Miura, M. Protective effect of lidocaine on the ischemic-reperfused rat heart: a phosphorus 31 nuclear magnetic resonance study. *Basic Res. Cardiol.* **1993**, *28*, 619–628.
- Ohmura, T.; Muramatsu, I.; Kigoshi, S.; Noguchi, H.; Muraoka, R.; Komoriya, Y.; Hayashi, H. Novel cardioprotective effects of TYB-3823 on ischemic damage in the working hearts of rats: comparison with lidocaine. *J. Pharmacol. Exp. Ther.* **1990**, *254*, 696–701.
- Vitola, J. V.; Forman, M. B.; Holsinger, J. P.; Atkinson, J. B.; Murray, J. J. Reduction of myocardial infarct size in rabbits and inhibition of activation of rabbit and human neutrophils by lidocaine. *Am. Heart J.* **1997**, *133*, 315–322.
- Wendland, M. F.; Saeed, M.; Kondo, C.; Derugin, N.; Higgins, C. B. Effect of lidocaine on acute regional myocardial ischemia and reperfusion in the cat. An in-vivo 31P magnetic resonance spectroscopy study. *Invest. Radiol.* **1993**, *28*, 619–628.
- Hatori, N.; Roberts, R. L.; Tadokoro, H.; et al. Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. *J. Cardiovasc. Pharmacol.* **1991**, *18*, 581–588.
- Lee, R.; Nitta, T.; Schmid, R. A.; Schuessler, R. B.; Harris, K. M.; Gay, W. A. Retrograde infusion of lidocaine or L-arginine before reperfusion reduces myocardial infarct size. *Ann. Thorac. Surg.* **1998**, *65*, 1353–1359.
- Lesnefsky, E. J.; Van Benthuyzen, K. M.; McMurtry, I. F.; Shikes, R. H.; Johnston, R. B.; Horwitz, L. D. Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product. *J. Cardiovasc. Pharmacol.* **1989**, *13*, 895–901.
- Koufaki, M.; Calogeropoulou, T.; Rekka, E.; Chryselis, M.; Papazafiri, P.; Gaitanaki, C.; Makriyannis, A. Bifunctional Agents for Reperfusion Arrhythmias: Novel Hybrid Vitamin E/Class I Antiarrhythmics. *Bioorg. Med. Chem.* **2003**, *11*, 5209–5219.
- Koufaki, M.; Kiziridi, C.; Papazafiri, P.; Vassilopoulos, A.; Varró, A.; Nagy, Z.; Farkas, A.; Makriyannis, A. Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. *Bioorg. Med. Chem.* **2006**, *14*, 6666–6678.

- (30) Zhang, W. H.; Chan, W. L.; Lin, Y. H.; Szeto, Y. S.; Lin, Y. C.; Yeung, C. H. Synthesis of hydroxyflavanones from substituted acetophenones and benzaldehydes in the presence of silica gel, boric acid and piperidine. *Heterocycles* **1997**, *45*, 71–75.
- (31) Kano, S.; Tanaka, Y.; Sugino, E.; Hibino, S. Reduction of some functional groups with titanium(IV) chloride/sodium borohydride. *Synthesis* **1980**, 695–697.
- (32) Phillips, G. B.; Morgan, T. K.; Nickish, K.; Lind, J. M.; Gomez, R. P.; Wohl, R. A.; Argentieri, T. M.; Sullivan, M. E. Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sotalol. *J. Med. Chem.* **1990**, *33*, 627–633.
- (33) Ouertani, M.; Girard, P.; Kagan, H. B. Selective Nitration of Phenols Catalyzed by Lanthanum(III) Nitrate. *Tetrahedron Lett.* **1982**, *23*, 4315–4318.
- (34) Ono, A.; Hiroi, M.; Shimazaki, K.; Reduction of aromatic nitro-compounds by the sodium borohydride–copper(I) chloride system. *Chem. Ind.* **1984**, 75.
- (35) Malen, C.; Lacoste, J.-M.; Vilaine, J.-P.; Lenaers, A. Acylaminophenol compounds. *U.S. Patent 5254590*, 1993.
- (36) Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha. *J. Med. Chem.* **2001**, *44*, 3838–3848.
- (37) Cava, M. P.; Leninson, M. I. Thionation Reactions of Lawesson Reagents. *Tetrahedron* **1985**, *41*, 5061–5087.
- (38) Lepore, S. D.; He, Y. Use of Sonication for the Coupling of Sterically Hindered Substrates in the Phenolic Mitsunobu Reaction. *J. Org. Chem.* **2003**, *68*, 8261–8263.
- (39) Caron, S.; Vasquez, E. Efficient Synthesis of [6-Chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]-acetic Acid, a Novel COX-2 Inhibitor. *J. Org. Chem.* **2003**, *68*, 4104–4107.
- (40) Heisler, B. E.; Ferrier, G. Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. *J. Pharmacol. Exp. Ther.* **1996**, *279*, 317–324.
- (41) Walker, M.; Curtis, M.; Hearse, D. The Lambeth Conventions: guidelines of the study of arrhythmias in ischemia, infarction, and reperfusion. *Cardiol. Res.* **1988**, *22*, 447–455.
- (42) (a) Ceconi, C.; Cargnoni, A.; Pasini, E.; Condorelli, E.; Curello, S.; Ferrari, R. Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury. *Am. J. Physiol. Heart Circ. Physiol.* **1991**, *260*, H1057–H1061. (b) Lefer, D. J.; Granger, N. Oxidative Stress and Cardiac Disease. *Am. J. Med.* **2000**, *109*, 315–323.
- (43) Draper, H. H.; Hardley, M. Malondialdehyde Determination as Index of Lipid Peroxidation. *Methods Enzymol.* **1990**, *186*, 283–293.
- (44) Lathrop, D. A.; Varró, A.; Nánási, P. P.; Bódi, I. I.; Takyi, E.; Pankucsi, C. Differences in the Effects of D- and DL-Sotalol on Isolated Human Ventricular Muscle: Electromechanical Activity after Beta-Adrenoceptor Stimulation. *J. Cardiovasc. Pharmacol. Ther.* **1996**, *1*, 65–74.
- (45) (a) Varro, A.; Elharrar, V.; Surawicz, B. Frequency-dependent effects of several class I antiarrhythmic drugs on V_{max} of action potential upstroke in canine cardiac Purkinje fibers. *J. Cardiovasc. Pharmacol.* **1985**, *7*, 482–492. (b) Varró, A.; Lathrop, D. A. Sotalol and mexiletine: combination of rate-dependent electrophysiological effects. *J. Cardiovasc. Pharmacol.* **1990**, *16*, 557–567. (c) Mátyus, P.; Varga, I.; Rettégi, T.; Simay, A.; Kállay, N.; Károlyházy, L.; Kocsis, A.; Varró, A.; Péntes, I.; Papp, J. G. Novel antiarrhythmic compounds with combined class IB and class III mode of action. *Curr. Med. Chem.* **2004**, *11*, 61–69.
- (46) Campbell, T. J.; Vaughan Williams, E. M. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcaïnide. *Cardiovasc. Res.* **1983**, *17*, 251–258.
- (47) Campbell, T. J. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle and provide a theoretical basis for their subclassification. *Cardiovasc. Res.* **1983**, *17*, 344–352.
- (48) Knilans, T. K.; Lathrop, D. A.; Nánási, P. P.; Schwartz, A.; Varró, A. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and V_{max} . *Br. J. Pharmacol.* **1991**, *103*, 1568–1572.
- (49) Papp, J. G.; Németh, M.; Krassó, I. I.; Mester, L.; Hála, O.; Varró, A. Differential Electrophysiologic Effects of Chronically Administered Amiodarone on Canine Purkinje Fibers versus Ventricular Muscle. *J. Cardiovasc. Pharmacol. Ther.* **1996**, *1*, 287–296.
- (50) Gerebtzoff, G.; Li-Blatter, X.; Fischer, H.; Frentzel, A.; Seelig, A. Halogenation of Drugs Enhances Membrane Binding and Permeation. *ChemBioChem* **2004**, *5*, 676–684.
- (51) (a) Achari, B.; Mandal, S. B.; Dutta, P. K.; Chowdhury, C. Perspectives on 1,4-benzoxazines and their 2,3-dihydro derivatives. *Synlett* **2004**, 2449–2467. (b) Cecchetti, V.; Tabarrini, O.; Sabatini, S. From Cromakalim to Different Structural Classes of K_{ATP} Channel Openers. *Curr. Top. Med. Chem.* **2006**, *6*, 1049–1068.
- (52) Ilaš, J.; Anderluh, P.; Dolenc, M. S.; Kikelj, D. Recent advances in the synthesis of 2H-1,4-benzoxazin-3-(4H)-ones and 3,4-dihydro-2H-1,4-benzoxazines. *Tetrahedron* **2005**, *61*, 7325–7348.
- (53) Rybczynski, P. J.; Zeck, R. E.; Dudash, J.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T. Benzoxazinones as PPAR α Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model. *J. Med. Chem.* **2004**, *47*, 196–209.
- (54) The corresponding compounds were detected by GC-MS but decomposed upon isolation.
- (55) (a) Pratt, C. M.; Camm, A. J.; Cooper, W.; Friedman, P. L.; MacNeil, D. J.; Moulton, K. M.; Pitt, B.; Schwartz, P. J.; Veltri, E. P.; Waldo, A. L. Mortality in the Survival With Oral D-sotalol (SWORD) trial: why did patients die? *Am. J. Cardiol.* **1998**, *81*, 869–876. (b) Waldo, A. L.; Camm, A. J.; deRuyter, H.; Friedman, P. L.; MacNeil, D. J.; Pauls, J. F.; Pitt, B.; Pratt, C. M.; Schwartz, P. J.; Veltri, E. P. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators Survival With Oral D-Sotalol. *Lancet* **1996**, *348*, 7–12. (c) Waldo, A. L.; Camm, A. J.; deRuyter, H.; Friedman, P. L.; MacNeil, D. J.; Pitt, B.; Pratt, C. M.; Rodda, B. E.; Schwartz, P. J. Survival with oral D-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). *Am. J. Cardiol.* **1995**, *75*, 1023–1027.

JM801228H